Cryosite Limited (ASX:CTE)

Market Cap	51.74M +55.9%
Revenue (ttm)	15.75M +22.6%
Net Income	2.18M +19.2%
EPS	0.04 +14.4%
Shares Out	48.81M
PE Ratio	24.69
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,397
Open	1.060
Previous Close	1.060
Day's Range	1.060 - 1.060
52-Week Range	0.660 - 1.300
Beta	0.15
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 10, 2026

About Cryosite

Cryosite Limited provides outsourced clinical trials logistic services in Australia. It operates through Ambient, cold, and frozen; Ultra-frozen and cryogenic; and Cord Blood segments. The Ambient, cold, and frozen segment provides good manufacturing practice (GMP) clinical trial materials, scheduled medicines, controlled drug storage, clinical ancillary supplies, medical devices, and commercial products with strict temperature requirements. The Ultra-frozen and cryogenic segment offers advanced therapy medicinal products (ATMPS), such as cell ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1999
• Employees: 25
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: CTE

Financial Performance

In fiscal year 2025, Cryosite's revenue was 14.12 million, an increase of 11.93% compared to the previous year's 12.61 million. Earnings were 1.88 million, an increase of 2.39%.